News | August 16, 2021
IOL Chemicals and Pharma commissions Unit-10 for Rs 28.69 crores
'Unit-9' for manufacturing Gabapentin & other pharma (APIs) products is expected to be complete in Q3FY22
'Unit-9' for manufacturing Gabapentin & other pharma (APIs) products is expected to be complete in Q3FY22
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
The company confirms an upward revision to its 2021 Outlook, reflecting the expectation to achieve mid-teens CER sales growth
In an exclusive interview with Rahul Koul of Indian Chemical News, Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc. USA shared details about the company's performance, R&D initiatives, Capex plan, CSR, and future outlook. Excerpts of the interview:
The company's operating revenue for Q4 FY21 was Rs. 330.2 crore
Adjusted PAT declined 18.8% YoY
Dr. Reddy's has the rights to distribute 250mn doses in India
The progress has been encouraging with approvals and launches in the US, EU, Japan, Australia and Emerging Markets. Post Mylan Upjohn (Pfizer) merger, the scope has been extended to China as well.
New agreement for three further production lines at Lonza’s site in Visp, Switzerland
Subscribe To Our Newsletter & Stay Updated
